Burlingame, CA, United States of America

Yinglin Han

This inventor holds 1 USPTO granted patent. Top assignee: Enanta Pharmaceuticals, Inc.. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yinglin Han. Retrieved from https://idiyas.com/inventor/yinglin-han

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yinglin Han - Innovator in Pharmaceutical Chemistry

Introduction

Yinglin Han is a notable inventor based in Burlingame, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of important chemical compounds. His work is essential for the development of new medications.

Latest Patents

Yinglin Han holds a patent for "Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine." This invention relates to novel methods for synthesizing a crucial reagent used in the production of bridged erythromycin derivatives and their respective pharmaceutically acceptable salts, as detailed in PCT Application WO 03/097659 A1. The patent highlights innovative processes and intermediates for preparing a compound of formula (Ia).

Career Highlights

Yinglin Han is currently associated with Enanta Pharmaceuticals, Inc., where he continues to advance his research in pharmaceutical development. His expertise in chemical synthesis has positioned him as a valuable asset in the industry.

Collaborations

Yinglin has collaborated with talented colleagues, including Datong Tang and Yanhe Huang, who contribute to the innovative environment at Enanta Pharmaceuticals.

Conclusion

Yinglin Han's work exemplifies the impact of innovative chemistry in the pharmaceutical industry. His contributions are paving the way for new therapeutic options and enhancing the field of drug development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…